Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Employer
-
Field
-
100%, Zurich, fixed-term The Musculoskeletal Bioengineering Laboratory, led by Prof. Dr. Tristan März, is an interdisciplinary research group focused on understanding the pathophysiology
-
on understanding, modeling, and engineering complex biological systems with an emphasis on medical and translational research. The assistant professorship is embedded in the newly established Botnar Institute
-
The Department of Biomedicine (DBM) is a joint effort between the University of Basel and the University Hospitals Basel. It unites basic and clinical scientists to advance our understanding
-
Diversity website to find out how we ensure a fair and open environment that allows everyone to grow and flourish. Sustainability is a core value for us – we are consistently working towards a climate-neutral
-
, including data management and the maintenance of computational infrastructure and software. Project background The position is part of the Institute of Microbiology at ETH Zurich and closely linked
-
data, spanning from whole-genome variant calling and decision support to single-cell sequencing analysis. We develop and extend robust analysis workflows and reusable components, in close collaboration
-
lab / external, we are seeking a post-doctoral researcher to join our team. In the project, we will be analyzing ride-sharing, shared e-scooter and shared bicycle behaviour. We will analyse the data
-
are offering a PhD position and a postdoctoral position. Project background The project RadiantDx is a multidisciplinary, collaborative project that addresses the diagnosis of sepsis. Sepsis is a severe health
-
100%, Basel, fixed-term The Computational Biology (CoBi) group, led by Prof. Dagmar Iber, develops data-driven, mechanistic models of biological systems using advanced imaging and computational
-
standard of quality in mind. Our Diagnostic division is the world leader in in-vitro diagnostics, our Pharmaceutical Division is the No. 1 supplier of cancer medicines. Capitalizing on the exciting